4Marc Fisher,Giora Feuerstein,David W. Howells,Patricia D. Hum,Thomas A. Kent,Sean I. Savitz,Eng H. Lo,吕志宿(译),罗本燕(译).卒中治疗专业学术圆桌会议临床前推荐更新版[J].国际脑血管病杂志,2009,17(8):561-567. 被引量：6
5Stroke therapy academic industry rotmdtable (Fisher M, Chair). Recommendations for stardards regarding preclinical neurotrotective and restorative tkug development. Stroke, 1999, 30: 2752-2758.
6O'Collins VE, Macleod MR, Donnan GA, et al. 1,026 experimental treatments in acute stroke. Ann Netrol, 2006, 59: 467-477.
7Savitz SI. A critical appraisal for the NXY-059 neuroprotection studies for acute stroke: A need for more rigorous testing of neuroprotective agents in animal stroke models. Exp Neurol, 2007, 205: 20-25.
8Macleod MR, O'Collins T, Horky LL, et al. Systematic review and metaanalysis of the efficacy of fk506 in experimental stroke. J Cereb Blood Flow Metab, 2005, 25: 713-721.
9Crossley NA, Sena E, Goehler J, et al. Empirical evidence of bias in the design of experimental stroke studies: A metaepidemiologic approach. Stroke, 2008, 39: 929-934.
10Macleod MR, van der Worp liB, Sena ES, et al. Evidence for the efficacy of nxy-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke, 2008, 39: 2824-2829.
